Octreotide LAR Depot

DRUG2 trials

Sponsors

Lexicon Pharmaceuticals, Virginia Commonwealth University

Conditions

Carcinoid SyndromeGastrointestinal Bleeding

Phase 1

Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)

CompletedNCT01707225

Virginia Commonwealth UniversityGastrointestinal Bleeding

Start: 2013-02-28End: 2014-10-31Updated: 2017-02-03

Phase 2

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

CompletedNCT00853047

Lexicon PharmaceuticalsCarcinoid Syndrome

Start: 2009-03-31End: 2014-06-30Updated: 2018-12-26

Related Papers

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach

Clinical Therapeutics2016-04-0147 citations